Biomarkers.

Background: The existing literature has established that Alzheimer's disease (AD) is typically characterized by changes in memory-associated temporal and parietal lobe atrophy and hypometabolism. However, some individuals clinically diagnosed with AD do not have biomarkers consistent with AD pathology. In this cross-sectional study, we aimed to investigate differences in memory consolidation, temporal and parietal lobe atrophy, as well as temporal and parietal lobe metabolism within a clinically diagnosed cohort of individuals with amnestic Mild Cognitive Impairment (aMCI) who were either positive or negative for amyloid.

Biomarkers.

Background: Known areas of Alzheimer's pathology, including the hippocampus, entorhinal cortex and medial temporal cortex, have been well-demonstrated as demonstrating atrophy in Alzheimer's disease (AD). Using surface-based morphometry measures, recent studies have suggested that the insula may play a role in memory function. Differences in patients based on amyloid biomarkers are increasingly being studied, particularly comparing individuals who were clinically diagnosed as AD but have negative amyloid biomarkers with those who are positive for amyloid.

The early-onset Alzheimer's disease MRI signature: a replication and extension analysis in early-stage AD.

Early-onset Alzheimer's disease (EOAD) is less investigated than the more common late-onset Alzheimer's disease (LOAD) despite its more aggressive course. A cortical signature of EOAD was recently proposed and may facilitate EOAD investigation. Here, we aimed to validate this proposed MRI biomarker of EOAD neurodegeneration in an Appalachian clinical cohort.

Memory consolidation, temporal and parietal atrophy, and metabolism in amyloid-β positive and negative mild cognitive impairment.

Background: Alzheimer's disease (AD) is classically characterized by alterations in memory consolidation. With the advent of diagnostic biomarkers, some patients clinically diagnosed with AD display biomarkers inconsistent with the diagnosis.

Objective: We aimed to explore differences in memory consolidation and neurodegeneration of the temporal and parietal lobes as a function of amyloid-β status in amnestic mild cognitive impairment (aMCI).

Executive function and cortical thickness in biomarker aMCI.

Introduction: Memory deficits are the primary symptom in amnestic Mild Cognitive Impairment (aMCI); however, executive function (EF) deficits are common. The current study examined EF in aMCI based upon amyloid status (A+/A-) and regional atrophy in signature areas of Alzheimer's disease (AD).

Method: Participants included 110 individuals with aMCI (A+ = 66; A- = 44) and 33 cognitively healthy participants (HP).

Healthcare Providers' Experiences of Caring for Patients With COVID-19 Requiring Extracorporeal Membrane Oxygenation Support.

Background: Coronavirus 19 (COVID-19) affected healthcare workers (HCW) in ways more than increasing the volume of patients needing care. Increased numbers of patients at younger ages required support with extracorporeal membrane oxygenation (ECMO). Providing this care requires an interdisciplinary team.

Targeted gene expression using a 1.1 kilobase promoter fragment of the tumour-associated antigen EpCAM.

The epithelial cell adhesion molecule EpCAM is over- or de novo expressed during carcinogenesis. EpCAM expression correlates with increased proliferation and dedifferentiation. Recently, we reported the cloning of a 1.